24114. Adulteration and misbranding of fluidextract of aconite, tincture of aconite, fluidextract of digitalis, and fluidextract of squill compound. U. S. -v. 5 Bottles of Fluidextract Aconite, et al. Default decrees of condemnation and destruction. (F. & D. nos. 34556 to 34559, incl. Sample nos. 22447-B, 22449-B, 22451-B, 22454-B.) These cases were based on shipments of fluidextract of aconite, a product recognized in the National Formulary, and of tincture of aconite, which was represented to be of pharmacopoeial standard, both of which products had a 14832—35 5 potency of less than three tenths of that required by the authority in which described; of a lot of fluidextract of digitalis, a product recognized in the National Formulary, and which was practically inert; and a lot of fluidextract of squill compound which when tested for the physiological activity of its squill content, was found to be practically devoid of activity. The fluidextract of aconite and fluidextract of digitalis, because of their low potency, would not produce certain curative and therapeutic effects claimed on the labels, in the dosages recommended. On December 17, 1934, the United States attorney for the Eastern District of Louisiana, acting upon a report by the Secretary of Agriculture, filed in the district court libels praying seizure and condemnation of 16 bottles of fluid- extract of aconite, 13 bottles of tincture of aconite, 8 bottles of fluidextract of digitalis, and 19 bottles of fluidextract of squill compound at New Orleans, La., alleging that the articles had been shipped in interstate commerce on or about March 27, 28, and 30, 1934, by the Southwestern Drug Corporation from Houston, Tex., and charging adulteration and misbranding in violation of the Food and Drugs Act as amended. The articles were alleged to be adulterated in the following respects: The fluidextract of aconite and the fluidextract of digitalis were sold under names recognized in the National Formulary, and differed from the standard of strength as determined by the tests laid down therein, and their own standard of strength was not stated on the container; the tincture of aconite was sold under a name recognized in the United States Pharmacopoeia, and differed from the standard of strength as determined by the test laid down therein, and its own standard of strength was not declared on the container; the strength of the fluidextract of squill compound fell below the standard or quality under which it was sold, namely, " Fluid Extract Squill Compound * * * Stand- ard of Strength—One Pint represents Squill * * * 8 troy ounces." Misbranding of the tincture of aconite, fluidextract of digitalis, and fluid- extract of squill compound was alleged for the reason that the statements, "Tinct. Aconite * * * U. S. P.", "Fluid * * * Extract Digitalis * * * Standard—1 Cc. representing 1 gram of the drug", " Fluid Extract Squill Compound * * * Standard of Strength—One Pint represents Squill * * * 8 troy ounces", were false and misleading. Misbranding of the fluidextract of aconite and fluidextract of digitalis was alleged for the reason that the following statements regarding the curative or therapeutic effects of the articles, (fluidextract of aconite) "Properties A powerful nerve and arte- rial sedative; anti-pyretic, lowering temperature, reducing pulse * * * Dose of the Fluid Extract—% to 2 minims (0.03 to 0.12 Cc.)", (fluidextract of digitalis) " Properties—Cardiac Tonic. Used in dropsy depending directly upon diseases of the heart. Useful in chronic bronchitis with profuse secretion, lessening pulmonary congestion and secretion. Uterine hemorrhage may be controlled by digitalis. * * * Dose of the Fluid Extract—% to 2 minims (0.03 to 0.12 Cc.)", were false and fraudulent, since the articles in the dosages stated on the labels would not produce the effects claimed. On January 8 and 11, 1935, no claimant having appeared, judgments of con- demnation were entered and it was ordered that the products be destroyed. M. L. WILSON, Acting Secretary of Agriculture.